Salt of Pyrrolo[2,3-d]pyrimidine Compound and Novel Polymorph of Salt
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,138,250 | Salt of Pyrrolo[2,3-d]pyrimidine Compound and Novel Polymorph of Salt In force · High confidence | Crystal Pharmatech Co., Ltd. | In force | High confidence | ||
| US 9,994,579 | Salt of Pyrrolo[2,3-d]pyrimidine Compound and Novel Polymorph of Salt Lapsed Jun 12, 2026 on the fee record Ended Jun 12, 2026 · High confidence | Crystal Pharmatech Co., Ltd. | Lapsed Jun 12, 2026 on the fee record | Ended Jun 12, 2026 | High confidence |
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Crystal Pharmatech Co., Ltd..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.